{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:56:44Z","timestamp":1790521004011,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015250","name":"NIHR Bristol Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejpn.2019.12.005","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:55:29Z","timestamp":1576612529000},"page":"43-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The concept of disease modification"],"prefix":"10.1016","volume":"24","author":[{"given":"J. Helen","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Lagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2019.12.005_bib1","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbadis.2017.02.003","article-title":"Novel therapeutic approaches for disease-modification of epileptogenisis for curing epilepsy","volume":"1803","author":"Clossen","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpn.2019.12.005_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14737175.2018.1455503","article-title":"Pediatric epilepsy surgery: the earlier the better","volume":"18","author":"Braun","year":"2018","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejpn.2019.12.005_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e31821527f0","article-title":"Long-term outcome after temporal lobe surgery in childhood: intellectual gains are correlated with brain volume change","volume":"76","author":"Skirrow","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ejpn.2019.12.005_bib4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/epi.14707","article-title":"Determinants of IQ outcome after focal epilepsy surgery in childhood: a longitudinal case-control neuroimaging study","volume":"60","author":"Skirrow","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.12.005_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1750-1172-8-176","article-title":"Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy","volume":"8","author":"Nabbout","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejpn.2019.12.005_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1528-1157.1998.tb01413.x","article-title":"Lamotrigine and seizure aggravation in severe myoclonic epilepsy","volume":"39","author":"Guerrini","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.12.005_bib7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/epi.14191","article-title":"Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes","volume":"59","author":"de Lange","year":"2018","journal-title":"Epilepsia"},{"issue":"Pt 10","key":"10.1016\/j.ejpn.2019.12.005_bib8","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awr129","article-title":"Dravet Syndrome as epileptic encephalopathy: evidence from very long-term course and neuropathology","volume":"134","author":"Catarino","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2019.12.005_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/dmcn.12593","article-title":"Lamotrigine can be beneficial in patients with Dravet Syndrome","volume":"57","author":"Dalic","year":"2015","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2019.12.005_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/dmcn.12096","article-title":"Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study","volume":"55","author":"Ramm-Pettersen","year":"2013","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ejpn.2019.12.005_bib11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1528-1167.2008.01715.x","article-title":"Electroencephalographic evolution of hypsarrhythmia: toward an early treatment option","volume":"49","author":"Philippi","year":"2008","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ejpn.2019.12.005_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","article-title":"TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients","volume":"12","author":"Kingswood","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejpn.2019.12.005_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"Jozwiak","year":"2011","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2019.12.005_bib14","article-title":"Early clinical predictors of autism spectrum disorder in infants with tuberous sclerosis complex: results from the EPISTOP study","volume":"8","author":"Moavero","year":"2019","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ejpn.2019.12.005_bib15","series-title":"EPISTOP and EPIMARKER Abstract","author":"Jozwiak","year":"2019"},{"key":"10.1016\/j.ejpn.2019.12.005_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1474-4422(15)00250-1","article-title":"The genetic landscape of the epileptic encephalopathies of infancy and childhood","volume":"15","author":"MacTague","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejpn.2019.12.005_bib17","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejpn.2019.12.005_bib18","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"278","author":"Schulz","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2019.12.005_bib19","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2019.12.005_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40265-018-0868-8","article-title":"Overview of current drugs and molecules in development for spinal muscular atrophy","volume":"78","author":"Shorrock","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejpn.2019.12.005_bib21","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41591-018-0103-x","article-title":"Biochemical autoregulatory gene therapy for focal epilepsy","volume":"24","author":"Lieb","year":"2018","journal-title":"Nat. Med."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379819304258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379819304258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:38:25Z","timestamp":1761071905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379819304258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":21,"alternative-id":["S1090379819304258"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2019.12.005","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The concept of disease modification","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2019.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}